ID   MK01_RAT                Reviewed;         358 AA.
AC   P63086; P27703;
DT   13-SEP-2004, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   02-OCT-2024, entry version 206.
DE   RecName: Full=Mitogen-activated protein kinase 1 {ECO:0000305};
DE            Short=MAP kinase 1;
DE            Short=MAPK 1;
DE            EC=2.7.11.24;
DE   AltName: Full=ERT1;
DE   AltName: Full=Extracellular signal-regulated kinase 2;
DE            Short=ERK-2;
DE   AltName: Full=MAP kinase isoform p42;
DE            Short=p42-MAPK;
DE   AltName: Full=Mitogen-activated protein kinase 2;
DE            Short=MAP kinase 2;
DE            Short=MAPK 2;
GN   Name=Mapk1 {ECO:0000312|RGD:70500}; Synonyms=Erk2, Mapk, Prkm1;
OS   Rattus norvegicus (Rat).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi; Mammalia;
OC   Eutheria; Euarchontoglires; Glires; Rodentia; Myomorpha; Muroidea; Muridae;
OC   Murinae; Rattus.
OX   NCBI_TaxID=10116;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA].
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RX   PubMed=2032290; DOI=10.1016/0092-8674(91)90098-j;
RA   Boulton T.G., Nye S.H., Robbins D.J., Ip N.Y., Radziejewska E.,
RA   Morgenbesser S.D., DePinho R.A., Panayotatos N., Cobb M.H.,
RA   Yancopoulos G.D.;
RT   "ERKs: a family of protein-serine/threonine kinases that are activated and
RT   tyrosine phosphorylated in response to insulin and NGF.";
RL   Cell 65:663-675(1991).
RN   [2]
RP   PROTEIN SEQUENCE OF 2-13; 69-75; 137-170; 193-201 AND 341-351, CLEAVAGE OF
RP   INITIATOR METHIONINE, ACETYLATION AT ALA-2, AND IDENTIFICATION BY MASS
RP   SPECTROMETRY.
RC   TISSUE=Pheochromocytoma;
RA   Bienvenut W.V., von Kriegsheim A.F., Kolch W.;
RL   Submitted (AUG-2006) to UniProtKB.
RN   [3]
RP   PROTEIN SEQUENCE OF 163-170, AND IDENTIFICATION BY MASS SPECTROMETRY.
RC   STRAIN=Sprague-Dawley; TISSUE=Brain;
RA   Lubec G., Kang S.U.;
RL   Submitted (JUL-2007) to UniProtKB.
RN   [4]
RP   AUTOPHOSPHORYLATION.
RX   PubMed=1712480; DOI=10.1073/pnas.88.14.6142;
RA   Seger R., Ahn N.G., Boulton T.G., Yancopoulos G.D., Panayotatos N.,
RA   Radziejewska E., Ericsson L., Bratlien R.L., Cobb M.H., Krebs E.G.;
RT   "Microtubule-associated protein 2 kinases, ERK1 and ERK2, undergo
RT   autophosphorylation on both tyrosine and threonine residues: implications
RT   for their mechanism of activation.";
RL   Proc. Natl. Acad. Sci. U.S.A. 88:6142-6146(1991).
RN   [5]
RP   PHOSPHORYLATION OF EIF4EBP1.
RX   PubMed=7939721; DOI=10.1126/science.7939721;
RA   Lin T.-A., Kong X., Haystead T.A.J., Pause A., Belsham G.J., Sonenberg N.,
RA   Lawrence J.C. Jr.;
RT   "PHAS-I as a link between mitogen-activated protein kinase and translation
RT   initiation.";
RL   Science 266:653-656(1994).
RN   [6]
RP   INTERACTION WITH ARRB2.
RX   PubMed=11226259; DOI=10.1073/pnas.041604898;
RA   Luttrell L.M., Roudabush F.L., Choy E.W., Miller W.E., Field M.E.,
RA   Pierce K.L., Lefkowitz R.J.;
RT   "Activation and targeting of extracellular signal-regulated kinases by
RT   beta-arrestin scaffolds.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:2449-2454(2001).
RN   [7]
RP   FUNCTION, AND INTERACTION WITH CDK2AP2.
RX   PubMed=12944431; DOI=10.1242/dev.00731;
RA   Terret M.E., Lefebvre C., Djiane A., Rassinier P., Moreau J., Maro B.,
RA   Verlhac M.H.;
RT   "DOC1R: a MAP kinase substrate that control microtubule organization of
RT   metaphase II mouse oocytes.";
RL   Development 130:5169-5177(2003).
RN   [8]
RP   INTERACTION WITH GIT1.
RX   PubMed=15923189; DOI=10.1074/jbc.m502271200;
RA   Yin G., Zheng Q., Yan C., Berk B.C.;
RT   "GIT1 is a scaffold for ERK1/2 activation in focal adhesions.";
RL   J. Biol. Chem. 280:27705-27712(2005).
RN   [9]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=16641100; DOI=10.1073/pnas.0600895103;
RA   Hoffert J.D., Pisitkun T., Wang G., Shen R.-F., Knepper M.A.;
RT   "Quantitative phosphoproteomics of vasopressin-sensitive renal cells:
RT   regulation of aquaporin-2 phosphorylation at two sites.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:7159-7164(2006).
RN   [10]
RP   INTERACTION WITH CAV2.
RX   PubMed=19778377; DOI=10.1111/j.1582-4934.2009.00391.x;
RA   Kwon H., Jeong K., Pak Y.;
RT   "Identification of pY19-caveolin-2 as a positive regulator of insulin-
RT   stimulated actin cytoskeleton-dependent mitogenesis.";
RL   J. Cell. Mol. Med. 13:1549-1564(2009).
RN   [11]
RP   INTERACTION WITH CAV2.
RX   PubMed=19427337; DOI=10.1016/j.bbamcr.2009.04.015;
RA   Kwon H., Jeong K., Hwang E.M., Park J.-Y., Hong S.-G., Choi W.-S., Pak Y.;
RT   "Caveolin-2 regulation of STAT3 transcriptional activation in response to
RT   insulin.";
RL   Biochim. Biophys. Acta 1793:1325-1333(2009).
RN   [12]
RP   REVIEW ON FUNCTION.
RX   PubMed=16393692; DOI=10.1080/02699050500284218;
RA   Yoon S., Seger R.;
RT   "The extracellular signal-regulated kinase: multiple substrates regulate
RT   diverse cellular functions.";
RL   Growth Factors 24:21-44(2006).
RN   [13]
RP   REVIEW ON FUNCTION, AND REVIEW ON SUBCELLULAR LOCATION.
RX   PubMed=19565474; DOI=10.1002/biof.52;
RA   Yao Z., Seger R.;
RT   "The ERK signaling cascade--views from different subcellular
RT   compartments.";
RL   BioFactors 35:407-416(2009).
RN   [14]
RP   REVIEW ON ACTIVITY REGULATION, AND REVIEW ON FUNCTION.
RX   PubMed=21779493; DOI=10.1177/1947601911407328;
RA   Wortzel I., Seger R.;
RT   "The ERK cascade: distinct functions within various subcellular
RT   organelles.";
RL   Genes Cancer 2:195-209(2011).
RN   [15]
RP   PHOSPHORYLATION [LARGE SCALE ANALYSIS] AT THR-183 AND TYR-185, AND
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22673903; DOI=10.1038/ncomms1871;
RA   Lundby A., Secher A., Lage K., Nordsborg N.B., Dmytriyev A., Lundby C.,
RA   Olsen J.V.;
RT   "Quantitative maps of protein phosphorylation sites across 14 different rat
RT   organs and tissues.";
RL   Nat. Commun. 3:876-876(2012).
RN   [16]
RP   SUBCELLULAR LOCATION, AND INTERACTION WITH CAVIN4.
RX   PubMed=24567387; DOI=10.1073/pnas.1315359111;
RA   Ogata T., Naito D., Nakanishi N., Hayashi Y.K., Taniguchi T., Miyagawa K.,
RA   Hamaoka T., Maruyama N., Matoba S., Ikeda K., Yamada H., Oh H., Ueyama T.;
RT   "MURC/Cavin-4 facilitates recruitment of ERK to caveolae and concentric
RT   cardiac hypertrophy induced by alpha1-adrenergic receptors.";
RL   Proc. Natl. Acad. Sci. U.S.A. 111:3811-3816(2014).
RN   [17]
RP   INTERACTION WITH DUSP7.
RX   PubMed=27783954; DOI=10.1016/j.celrep.2016.10.007;
RA   Tischer T., Schuh M.;
RT   "The phosphatase Dusp7 drives meiotic resumption and chromosome alignment
RT   in mouse oocytes.";
RL   Cell Rep. 17:1426-1437(2016).
RN   [18]
RP   X-RAY CRYSTALLOGRAPHY (2.3 ANGSTROMS).
RX   PubMed=8107865; DOI=10.1038/367704a0;
RA   Zhang F., Strand A., Robbins D., Cobb M.H., Goldsmith E.J.;
RT   "Atomic structure of the MAP kinase ERK2 at 2.3-A resolution.";
RL   Nature 367:704-710(1994).
RN   [19]
RP   X-RAY CRYSTALLOGRAPHY (2.80 ANGSTROMS) IN COMPLEX WITH ATP.
RX   PubMed=8639522; DOI=10.1021/bi952723e;
RA   Robinson M.J., Harkins P.C., Zhang J., Baer R., Haycock J.W., Cobb M.H.,
RA   Goldsmith E.J.;
RT   "Mutation of position 52 in ERK2 creates a nonproductive binding mode for
RT   adenosine 5'-triphosphate.";
RL   Biochemistry 35:5641-5646(1996).
RN   [20]
RP   X-RAY CRYSTALLOGRAPHY (2.4 ANGSTROMS).
RX   PubMed=9298898; DOI=10.1016/s0092-8674(00)80351-7;
RA   Canagarajah B.J., Khokhlatchev A., Cobb M.H., Goldsmith E.J.;
RT   "Activation mechanism of the MAP kinase ERK2 by dual phosphorylation.";
RL   Cell 90:859-869(1997).
RN   [21]
RP   X-RAY CRYSTALLOGRAPHY (2.10 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=9753691; DOI=10.1016/s0969-2126(98)00113-0;
RA   Wang Z., Canagarajah B.J., Boehm J.C., Kassisa S., Cobb M.H., Young P.R.,
RA   Abdel-Meguid S., Adams J.L., Goldsmith E.J.;
RT   "Structural basis of inhibitor selectivity in MAP kinases.";
RL   Structure 6:1117-1128(1998).
RN   [22]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 2-357, AND INTERACTION WITH
RP   DUSP6.
RX   PubMed=16567630; DOI=10.1073/pnas.0510506103;
RA   Liu S., Sun J.P., Zhou B., Zhang Z.Y.;
RT   "Structural basis of docking interactions between ERK2 and MAP kinase
RT   phosphatase 3.";
RL   Proc. Natl. Acad. Sci. U.S.A. 103:5326-5331(2006).
RN   [23]
RP   X-RAY CRYSTALLOGRAPHY (1.90 ANGSTROMS) OF 2-357.
RX   PubMed=16765894; DOI=10.1016/j.str.2006.04.006;
RA   Zhou T., Sun L., Humphreys J., Goldsmith E.J.;
RT   "Docking interactions induce exposure of activation loop in the MAP kinase
RT   ERK2.";
RL   Structure 14:1011-1019(2006).
RN   [24]
RP   X-RAY CRYSTALLOGRAPHY (2.50 ANGSTROMS) OF 2-358 IN COMPLEX WITH INHIBITOR.
RX   PubMed=18571434; DOI=10.1016/j.jsb.2008.05.002;
RA   Rastelli G., Rosenfeld R., Reid R., Santi D.V.;
RT   "Molecular modeling and crystal structure of ERK2-hypothemycin complexes.";
RL   J. Struct. Biol. 164:18-23(2008).
RN   [25]
RP   X-RAY CRYSTALLOGRAPHY (2.41 ANGSTROMS) IN COMPLEX WITH INHIBITOR.
RX   PubMed=18767165; DOI=10.1002/prot.22207;
RA   Katayama N., Orita M., Yamaguchi T., Hisamichi H., Kuromitsu S.,
RA   Kurihara H., Sakashita H., Matsumoto Y., Fujita S., Niimi T.;
RT   "Identification of a key element for hydrogen-bonding patterns between
RT   protein kinases and their inhibitors.";
RL   Proteins 73:795-801(2008).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (1.95 ANGSTROMS) IN COMPLEX WITH DCC, FUNCTION IN
RP   PHOSPHORYLATION OF DCC, INTERACTION WITH DCC, AND MUTAGENESIS OF GLN-117;
RP   HIS-123 AND LEU-155.
RX   PubMed=21070949; DOI=10.1016/j.str.2010.08.011;
RA   Ma W., Shang Y., Wei Z., Wen W., Wang W., Zhang M.;
RT   "Phosphorylation of DCC by ERK2 is facilitated by direct docking of the
RT   receptor P1 domain to the kinase.";
RL   Structure 18:1502-1511(2010).
CC   -!- FUNCTION: Serine/threonine kinase which acts as an essential component
CC       of the MAP kinase signal transduction pathway. MAPK1/ERK2 and
CC       MAPK3/ERK1 are the 2 MAPKs which play an important role in the MAPK/ERK
CC       cascade. They participate also in a signaling cascade initiated by
CC       activated KIT and KITLG/SCF. Depending on the cellular context, the
CC       MAPK/ERK cascade mediates diverse biological functions such as cell
CC       growth, adhesion, survival and differentiation through the regulation
CC       of transcription, translation, cytoskeletal rearrangements. The
CC       MAPK/ERK cascade also plays a role in initiation and regulation of
CC       meiosis, mitosis, and postmitotic functions in differentiated cells by
CC       phosphorylating a number of transcription factors. About 160 substrates
CC       have already been discovered for ERKs. Many of these substrates are
CC       localized in the nucleus, and seem to participate in the regulation of
CC       transcription upon stimulation. However, other substrates are found in
CC       the cytosol as well as in other cellular organelles, and those are
CC       responsible for processes such as translation, mitosis and apoptosis.
CC       Moreover, the MAPK/ERK cascade is also involved in the regulation of
CC       the endosomal dynamics, including lysosome processing and endosome
CC       cycling through the perinuclear recycling compartment (PNRC); as well
CC       as in the fragmentation of the Golgi apparatus during mitosis. The
CC       substrates include transcription factors (such as ATF2, BCL6, ELK1,
CC       ERF, FOS, HSF4 or SPZ1), cytoskeletal elements (such as CANX, CTTN,
CC       GJA1, MAP2, MAPT, PXN, SORBS3 or STMN1), regulators of apoptosis (such
CC       as BAD, BTG2, CASP9, DAPK1, IER3, MCL1 or PPARG), regulators of
CC       translation (such as EIF4EBP1 and FXR1) and a variety of other
CC       signaling-related molecules (like ARHGEF2, DCC, FRS2 or GRB10). Protein
CC       kinases (such as RAF1, RPS6KA1/RSK1, RPS6KA3/RSK2, RPS6KA2/RSK3,
CC       RPS6KA6/RSK4, SYK, MKNK1/MNK1, MKNK2/MNK2, RPS6KA5/MSK1, RPS6KA4/MSK2,
CC       MAPKAPK3 or MAPKAPK5) and phosphatases (such as DUSP1, DUSP4, DUSP6 or
CC       DUSP16) are other substrates which enable the propagation the MAPK/ERK
CC       signal to additional cytosolic and nuclear targets, thereby extending
CC       the specificity of the cascade. Mediates phosphorylation of TPR in
CC       response to EGF stimulation. May play a role in the spindle assembly
CC       checkpoint. Phosphorylates PML and promotes its interaction with PIN1,
CC       leading to PML degradation (By similarity). Phosphorylates CDK2AP2
CC       (PubMed:12944431). {ECO:0000250|UniProtKB:P28482,
CC       ECO:0000269|PubMed:12944431, ECO:0000269|PubMed:21070949,
CC       ECO:0000303|PubMed:16393692, ECO:0000303|PubMed:19565474,
CC       ECO:0000303|PubMed:21779493}.
CC   -!- FUNCTION: Acts as a transcriptional repressor. Binds to a [GC]AAA[GC]
CC       consensus sequence. Repress the expression of interferon gamma-induced
CC       genes. Seems to bind to the promoter of CCL5, DMP1, IFIH1, IFITM1,
CC       IRF7, IRF9, LAMP3, OAS1, OAS2, OAS3 and STAT1. Transcriptional activity
CC       is independent of kinase activity. {ECO:0000250|UniProtKB:P28482}.
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-seryl-[protein] = ADP + H(+) + O-phospho-L-seryl-
CC         [protein]; Xref=Rhea:RHEA:17989, Rhea:RHEA-COMP:9863, Rhea:RHEA-
CC         COMP:11604, ChEBI:CHEBI:15378, ChEBI:CHEBI:29999, ChEBI:CHEBI:30616,
CC         ChEBI:CHEBI:83421, ChEBI:CHEBI:456216; EC=2.7.11.24;
CC   -!- CATALYTIC ACTIVITY:
CC       Reaction=ATP + L-threonyl-[protein] = ADP + H(+) + O-phospho-L-
CC         threonyl-[protein]; Xref=Rhea:RHEA:46608, Rhea:RHEA-COMP:11060,
CC         Rhea:RHEA-COMP:11605, ChEBI:CHEBI:15378, ChEBI:CHEBI:30013,
CC         ChEBI:CHEBI:30616, ChEBI:CHEBI:61977, ChEBI:CHEBI:456216;
CC         EC=2.7.11.24;
CC   -!- COFACTOR:
CC       Name=Mg(2+); Xref=ChEBI:CHEBI:18420; Evidence={ECO:0000250};
CC   -!- ACTIVITY REGULATION: Phosphorylated by MAP2K1/MEK1 and MAP2K2/MEK2 on
CC       Thr-183 and Tyr-185 in response to external stimuli like insulin or
CC       NGF. Both phosphorylations are required for activity. This
CC       phosphorylation causes dramatic conformational changes, which enable
CC       full activation and interaction of MAPK1/ERK2 with its substrates.
CC       Phosphorylation on Ser-27 by SGK1 results in its activation by
CC       enhancing its interaction with MAP2K1/MEK1 and MAP2K2/MEK2.
CC       Dephosphorylated and inactivated by DUSP1, DUSP3, DUSP6 and DUSP9.
CC       Inactivated by pyrimidylpyrrole inhibitors.
CC   -!- SUBUNIT: Binds both upstream activators and downstream substrates in
CC       multimolecular complexes. Interacts with ADAM15, ARHGEF2, DAPK1 (via
CC       death domain), HSF4, IER3, IPO7, MKNK2, MORG1, NISCH, PEA15, SGK1, and
CC       isoform 1 of NEK2 (By similarity). Interacts (via phosphorylated form)
CC       with TPR (via C-terminal region and phosphorylated form); the
CC       interaction requires dimerization of MAPK1/ERK2 and increases following
CC       EGF stimulation (By similarity). Interacts with MAP2K1 (By similarity).
CC       Interacts with DUSP6 (PubMed:16567630). Interacts with ARRB2
CC       (PubMed:11226259). Interacts (phosphorylated form) with CAV2 ('Tyr-19'-
CC       phosphorylated form); the interaction, promoted by insulin, leads to
CC       nuclear location and MAPK1 activation (PubMed:19427337,
CC       PubMed:19778377). MKNK2 isoform 1 binding prevents from
CC       dephosphorylation and inactivation (By similarity). Interacts with DCC
CC       (PubMed:21070949). The phosphorylated form interacts with PML (By
CC       similarity). Interacts with STYX (By similarity). Interacts with
CC       CDK2AP2 (PubMed:12944431). Interacts with CAVIN4 (PubMed:24567387).
CC       Interacts with DUSP7; the interaction enhances DUSP7 phosphatase
CC       activity (PubMed:27783954). Interacts with GIT1; this interaction is
CC       necessary for MAPK1 localization to focal adhesions (PubMed:15923189).
CC       Interacts with ZNF263 (By similarity). {ECO:0000250|UniProtKB:P28482,
CC       ECO:0000250|UniProtKB:P63085, ECO:0000269|PubMed:11226259,
CC       ECO:0000269|PubMed:12944431, ECO:0000269|PubMed:15923189,
CC       ECO:0000269|PubMed:16567630, ECO:0000269|PubMed:19427337,
CC       ECO:0000269|PubMed:19778377, ECO:0000269|PubMed:21070949,
CC       ECO:0000269|PubMed:24567387, ECO:0000269|PubMed:27783954}.
CC   -!- INTERACTION:
CC       P63086; Q63155: Dcc; NbExp=10; IntAct=EBI-397710, EBI-1798965;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm, cytoskeleton, spindle {ECO:0000250}.
CC       Nucleus {ECO:0000250}. Cytoplasm, cytoskeleton, microtubule organizing
CC       center, centrosome {ECO:0000250}. Cytoplasm
CC       {ECO:0000269|PubMed:24567387}. Membrane, caveola
CC       {ECO:0000269|PubMed:24567387}. Cell junction, focal adhesion
CC       {ECO:0000250|UniProtKB:P63085}. Note=Associated with the spindle during
CC       prometaphase and metaphase. PEA15-binding and phosphorylated DAPK1
CC       promote its cytoplasmic retention. Phosphorylation at Ser- 244 and Ser-
CC       246 as well as autophosphorylation at Thr-188 promote nuclear
CC       localization. {ECO:0000250}.
CC   -!- TISSUE SPECIFICITY: Highest levels within the nervous system, expressed
CC       in different tissues, mostly in muscle, thymus and heart.
CC   -!- DEVELOPMENTAL STAGE: Increased expression during development.
CC   -!- DOMAIN: The TXY motif contains the threonine and tyrosine residues
CC       whose phosphorylation activates the MAP kinases.
CC   -!- PTM: Dually phosphorylated on Thr-183 and Tyr-185, which activates the
CC       enzyme. Phosphorylated upon FLT3 and KIT signaling. Ligand-activated
CC       ALK induces tyrosine phosphorylation (By similarity). Dephosphorylated
CC       by PTPRJ at Tyr-185 (By similarity). Autophosphorylated on threonine
CC       and tyrosine residues in vitro, which correlates with a slow and low
CC       level of activation. Phosphorylation on Ser-27 by SGK1 results in its
CC       activation by enhancing its interaction with MAP2K1/MEK1 and
CC       MAP2K2/MEK2 (By similarity). Dephosphorylated by DUSP1 and DUSP2 at
CC       Thr-183 and Tyr-185 (By similarity). {ECO:0000250|UniProtKB:P28482,
CC       ECO:0000250|UniProtKB:P63085}.
CC   -!- PTM: ISGylated. {ECO:0000250}.
CC   -!- PTM: Ubiquitinated by TRIM15 via 'Lys-63'-linked ubiquitination;
CC       leading to activation. Deubiquitinated by CYLD.
CC       {ECO:0000250|UniProtKB:P27361}.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. CMGC Ser/Thr
CC       protein kinase family. MAP kinase subfamily. {ECO:0000305}.
CC   ---------------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see https://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution (CC BY 4.0) License
CC   ---------------------------------------------------------------------------
DR   EMBL; M64300; AAA41124.1; -; mRNA.
DR   PIR; A40033; A40033.
DR   RefSeq; NP_446294.1; NM_053842.2.
DR   RefSeq; XP_006248720.1; XM_006248658.3.
DR   RefSeq; XP_006248721.1; XM_006248659.3.
DR   RefSeq; XP_008767070.1; XM_008768848.2.
DR   PDB; 1GOL; X-ray; 2.80 A; A=1-358.
DR   PDB; 2ERK; X-ray; 2.40 A; A=1-358.
DR   PDB; 2FYS; X-ray; 2.50 A; A/B=2-358.
DR   PDB; 2GPH; X-ray; 1.90 A; A=2-358.
DR   PDB; 2Z7L; X-ray; 2.41 A; A=1-358.
DR   PDB; 3C9W; X-ray; 2.50 A; A/B=2-358.
DR   PDB; 3ERK; X-ray; 2.10 A; A=1-358.
DR   PDB; 3O71; X-ray; 1.95 A; A=1-358.
DR   PDB; 3QYW; X-ray; 1.50 A; A=1-358.
DR   PDB; 3QYZ; X-ray; 1.46 A; A=1-358.
DR   PDB; 3R63; X-ray; 1.70 A; A=1-358.
DR   PDB; 3ZU7; X-ray; 1.97 A; A=3-358.
DR   PDB; 3ZUV; X-ray; 2.72 A; A/C=3-358.
DR   PDB; 4ERK; X-ray; 2.20 A; A=1-358.
DR   PDB; 4GSB; X-ray; 1.80 A; A=1-358.
DR   PDB; 4GT3; X-ray; 1.68 A; A=1-358.
DR   PDB; 4GVA; X-ray; 1.83 A; A=1-358.
DR   PDB; 4I5H; X-ray; 1.90 A; A=2-358.
DR   PDB; 4N4S; X-ray; 2.20 A; A/B=2-358.
DR   PDB; 4QYY; X-ray; 1.65 A; A=1-358.
DR   PDB; 4S2Z; X-ray; 1.48 A; A=1-358.
DR   PDB; 4S30; X-ray; 2.00 A; A=1-358.
DR   PDB; 4S31; X-ray; 1.45 A; A=1-358.
DR   PDB; 4S32; X-ray; 1.34 A; A=1-358.
DR   PDB; 4S33; X-ray; 1.48 A; A=1-358.
DR   PDB; 4S34; X-ray; 2.50 A; A=1-358.
DR   PDB; 4XNE; X-ray; 1.80 A; A=9-354.
DR   PDB; 4XOY; X-ray; 2.10 A; A=8-358.
DR   PDB; 4XOZ; X-ray; 1.95 A; A=8-358.
DR   PDB; 4XP0; X-ray; 1.46 A; A=8-358.
DR   PDB; 4XP2; X-ray; 1.75 A; A=8-358.
DR   PDB; 4XP3; X-ray; 1.78 A; A=8-358.
DR   PDB; 4XRJ; X-ray; 1.69 A; A=9-354.
DR   PDB; 4XRL; X-ray; 2.55 A; A=9-353.
DR   PDB; 5HD4; X-ray; 1.45 A; A=1-358.
DR   PDB; 5HD7; X-ray; 1.69 A; A=1-358.
DR   PDB; 5KE0; X-ray; 1.68 A; A=1-358.
DR   PDB; 5U6I; X-ray; 1.69 A; A=1-358.
DR   PDB; 5UMO; X-ray; 2.26 A; A=4-354.
DR   PDB; 6CPW; X-ray; 1.85 A; A=1-358.
DR   PDB; 6DCG; X-ray; 1.45 A; A=1-358.
DR   PDB; 6FI3; X-ray; 1.52 A; A=1-358.
DR   PDB; 6FI6; X-ray; 1.65 A; A=1-358.
DR   PDB; 6FJ0; X-ray; 1.66 A; A=1-358.
DR   PDB; 6FJB; X-ray; 1.85 A; A=1-358.
DR   PDB; 6FJZ; X-ray; 1.86 A; A=1-358.
DR   PDB; 6FLE; X-ray; 1.48 A; A=1-358.
DR   PDB; 6FLV; X-ray; 1.91 A; A=1-358.
DR   PDB; 6FMA; X-ray; 1.67 A; A=1-358.
DR   PDB; 6FN5; X-ray; 1.93 A; A=1-358.
DR   PDB; 6FQ7; X-ray; 1.60 A; A=1-358.
DR   PDB; 6FR1; X-ray; 1.56 A; A=1-358.
DR   PDB; 6FRP; X-ray; 1.53 A; A=1-358.
DR   PDB; 6FXV; X-ray; 1.53 A; A=1-358.
DR   PDB; 6OPK; X-ray; 2.54 A; A=7-358.
DR   PDB; 6OT6; X-ray; 1.65 A; A=1-358.
DR   PDB; 6OTS; X-ray; 2.10 A; A=1-358.
DR   PDB; 6RFO; X-ray; 1.70 A; A=1-163, A=200-358.
DR   PDB; 6RFP; X-ray; 1.74 A; A=1-358.
DR   PDB; 7UGB; X-ray; 1.90 A; A=3-358.
DR   PDBsum; 1GOL; -.
DR   PDBsum; 2ERK; -.
DR   PDBsum; 2FYS; -.
DR   PDBsum; 2GPH; -.
DR   PDBsum; 2Z7L; -.
DR   PDBsum; 3C9W; -.
DR   PDBsum; 3ERK; -.
DR   PDBsum; 3O71; -.
DR   PDBsum; 3QYW; -.
DR   PDBsum; 3QYZ; -.
DR   PDBsum; 3R63; -.
DR   PDBsum; 3ZU7; -.
DR   PDBsum; 3ZUV; -.
DR   PDBsum; 4ERK; -.
DR   PDBsum; 4GSB; -.
DR   PDBsum; 4GT3; -.
DR   PDBsum; 4GVA; -.
DR   PDBsum; 4I5H; -.
DR   PDBsum; 4N4S; -.
DR   PDBsum; 4QYY; -.
DR   PDBsum; 4S2Z; -.
DR   PDBsum; 4S30; -.
DR   PDBsum; 4S31; -.
DR   PDBsum; 4S32; -.
DR   PDBsum; 4S33; -.
DR   PDBsum; 4S34; -.
DR   PDBsum; 4XNE; -.
DR   PDBsum; 4XOY; -.
DR   PDBsum; 4XOZ; -.
DR   PDBsum; 4XP0; -.
DR   PDBsum; 4XP2; -.
DR   PDBsum; 4XP3; -.
DR   PDBsum; 4XRJ; -.
DR   PDBsum; 4XRL; -.
DR   PDBsum; 5HD4; -.
DR   PDBsum; 5HD7; -.
DR   PDBsum; 5KE0; -.
DR   PDBsum; 5U6I; -.
DR   PDBsum; 5UMO; -.
DR   PDBsum; 6CPW; -.
DR   PDBsum; 6DCG; -.
DR   PDBsum; 6FI3; -.
DR   PDBsum; 6FI6; -.
DR   PDBsum; 6FJ0; -.
DR   PDBsum; 6FJB; -.
DR   PDBsum; 6FJZ; -.
DR   PDBsum; 6FLE; -.
DR   PDBsum; 6FLV; -.
DR   PDBsum; 6FMA; -.
DR   PDBsum; 6FN5; -.
DR   PDBsum; 6FQ7; -.
DR   PDBsum; 6FR1; -.
DR   PDBsum; 6FRP; -.
DR   PDBsum; 6FXV; -.
DR   PDBsum; 6OPK; -.
DR   PDBsum; 6OT6; -.
DR   PDBsum; 6OTS; -.
DR   PDBsum; 6RFO; -.
DR   PDBsum; 6RFP; -.
DR   PDBsum; 7UGB; -.
DR   AlphaFoldDB; P63086; -.
DR   BMRB; P63086; -.
DR   SMR; P63086; -.
DR   BioGRID; 250505; 176.
DR   DIP; DIP-29117N; -.
DR   ELM; P63086; -.
DR   IntAct; P63086; 15.
DR   MINT; P63086; -.
DR   STRING; 10116.ENSRNOP00000002533; -.
DR   BindingDB; P63086; -.
DR   ChEMBL; CHEMBL5233; -.
DR   CarbonylDB; P63086; -.
DR   GlyGen; P63086; 1 site, 1 O-linked glycan (1 site).
DR   iPTMnet; P63086; -.
DR   PhosphoSitePlus; P63086; -.
DR   jPOST; P63086; -.
DR   PaxDb; 10116-ENSRNOP00000002533; -.
DR   Ensembl; ENSRNOT00000002533.8; ENSRNOP00000002533.6; ENSRNOG00000001849.8.
DR   Ensembl; ENSRNOT00055006213; ENSRNOP00055004732; ENSRNOG00055003901.
DR   Ensembl; ENSRNOT00060004151; ENSRNOP00060002931; ENSRNOG00060002574.
DR   Ensembl; ENSRNOT00065013385; ENSRNOP00065009913; ENSRNOG00065008439.
DR   GeneID; 116590; -.
DR   KEGG; rno:116590; -.
DR   AGR; RGD:70500; -.
DR   CTD; 5594; -.
DR   RGD; 70500; Mapk1.
DR   eggNOG; KOG0660; Eukaryota.
DR   GeneTree; ENSGT00940000156771; -.
DR   HOGENOM; CLU_000288_181_1_1; -.
DR   InParanoid; P63086; -.
DR   OrthoDB; 158564at2759; -.
DR   PhylomeDB; P63086; -.
DR   BRENDA; 2.7.11.24; 5301.
DR   Reactome; R-RNO-111995; phospho-PLA2 pathway.
DR   Reactome; R-RNO-112409; RAF-independent MAPK1/3 activation.
DR   Reactome; R-RNO-112411; MAPK1 (ERK2) activation.
DR   Reactome; R-RNO-1181150; Signaling by NODAL.
DR   Reactome; R-RNO-1295596; Spry regulation of FGF signaling.
DR   Reactome; R-RNO-1502540; Signaling by Activin.
DR   Reactome; R-RNO-162658; Golgi Cisternae Pericentriolar Stack Reorganization.
DR   Reactome; R-RNO-170968; Frs2-mediated activation.
DR   Reactome; R-RNO-198753; ERK/MAPK targets.
DR   Reactome; R-RNO-202670; ERKs are inactivated.
DR   Reactome; R-RNO-2029482; Regulation of actin dynamics for phagocytic cup formation.
DR   Reactome; R-RNO-2173795; Downregulation of SMAD2/3:SMAD4 transcriptional activity.
DR   Reactome; R-RNO-2173796; SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription.
DR   Reactome; R-RNO-2559580; Oxidative Stress Induced Senescence.
DR   Reactome; R-RNO-2559582; Senescence-Associated Secretory Phenotype (SASP).
DR   Reactome; R-RNO-2559585; Oncogene Induced Senescence.
DR   Reactome; R-RNO-2871796; FCERI mediated MAPK activation.
DR   Reactome; R-RNO-3371453; Regulation of HSF1-mediated heat shock response.
DR   Reactome; R-RNO-375165; NCAM signaling for neurite out-growth.
DR   Reactome; R-RNO-437239; Recycling pathway of L1.
DR   Reactome; R-RNO-445144; Signal transduction by L1.
DR   Reactome; R-RNO-450341; Activation of the AP-1 family of transcription factors.
DR   Reactome; R-RNO-456926; Thrombin signalling through proteinase activated receptors (PARs).
DR   Reactome; R-RNO-5654726; Negative regulation of FGFR1 signaling.
DR   Reactome; R-RNO-5654727; Negative regulation of FGFR2 signaling.
DR   Reactome; R-RNO-5654732; Negative regulation of FGFR3 signaling.
DR   Reactome; R-RNO-5654733; Negative regulation of FGFR4 signaling.
DR   Reactome; R-RNO-5663213; RHO GTPases Activate WASPs and WAVEs.
DR   Reactome; R-RNO-5668599; RHO GTPases Activate NADPH Oxidases.
DR   Reactome; R-RNO-5673001; RAF/MAP kinase cascade.
DR   Reactome; R-RNO-5674135; MAP2K and MAPK activation.
DR   Reactome; R-RNO-5674499; Negative feedback regulation of MAPK pathway.
DR   Reactome; R-RNO-5675221; Negative regulation of MAPK pathway.
DR   Reactome; R-RNO-6798695; Neutrophil degranulation.
DR   Reactome; R-RNO-6811558; PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling.
DR   Reactome; R-RNO-74749; Signal attenuation.
DR   Reactome; R-RNO-877300; Interferon gamma signaling.
DR   Reactome; R-RNO-881907; Gastrin-CREB signalling pathway via PKC and MAPK.
DR   Reactome; R-RNO-9627069; Regulation of the apoptosome activity.
DR   Reactome; R-RNO-9634635; Estrogen-stimulated signaling through PRKCZ.
DR   Reactome; R-RNO-9634638; Estrogen-dependent nuclear events downstream of ESR-membrane signaling.
DR   Reactome; R-RNO-9732724; IFNG signaling activates MAPKs.
DR   Reactome; R-RNO-982772; Growth hormone receptor signaling.
DR   Reactome; R-RNO-9856649; Transcriptional and post-translational regulation of MITF-M expression and activity.
DR   EvolutionaryTrace; P63086; -.
DR   PRO; PR:P63086; -.
DR   Proteomes; UP000002494; Chromosome 11.
DR   Bgee; ENSRNOG00000001849; Expressed in frontal cortex and 19 other cell types or tissues.
DR   GO; GO:0030424; C:axon; IDA:RGD.
DR   GO; GO:0005901; C:caveola; IDA:UniProtKB.
DR   GO; GO:0005813; C:centrosome; IEA:UniProtKB-SubCell.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005856; C:cytoskeleton; TAS:UniProtKB.
DR   GO; GO:0005829; C:cytosol; ISO:RGD.
DR   GO; GO:0032839; C:dendrite cytoplasm; IDA:RGD.
DR   GO; GO:0005769; C:early endosome; TAS:UniProtKB.
DR   GO; GO:0005925; C:focal adhesion; TAS:UniProtKB.
DR   GO; GO:0005794; C:Golgi apparatus; TAS:UniProtKB.
DR   GO; GO:0005770; C:late endosome; TAS:UniProtKB.
DR   GO; GO:0005739; C:mitochondrion; ISO:RGD.
DR   GO; GO:0072686; C:mitotic spindle; ISS:UniProtKB.
DR   GO; GO:0005654; C:nucleoplasm; IDA:UniProtKB.
DR   GO; GO:0005634; C:nucleus; ISO:RGD.
DR   GO; GO:0043204; C:perikaryon; IDA:RGD.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0014069; C:postsynaptic density; IDA:SynGO.
DR   GO; GO:0032991; C:protein-containing complex; IDA:RGD.
DR   GO; GO:0031143; C:pseudopodium; ISO:RGD.
DR   GO; GO:0005524; F:ATP binding; IDA:RGD.
DR   GO; GO:0003690; F:double-stranded DNA binding; IDA:RGD.
DR   GO; GO:0042802; F:identical protein binding; ISO:RGD.
DR   GO; GO:0016301; F:kinase activity; ISO:RGD.
DR   GO; GO:0004707; F:MAP kinase activity; IDA:UniProtKB.
DR   GO; GO:0031435; F:mitogen-activated protein kinase kinase kinase binding; IPI:RGD.
DR   GO; GO:0019902; F:phosphatase binding; ISO:RGD.
DR   GO; GO:0001784; F:phosphotyrosine residue binding; ISO:RGD.
DR   GO; GO:0004672; F:protein kinase activity; ISO:RGD.
DR   GO; GO:0019901; F:protein kinase binding; IPI:RGD.
DR   GO; GO:0106310; F:protein serine kinase activity; IEA:RHEA.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; IDA:MGI.
DR   GO; GO:0008353; F:RNA polymerase II CTD heptapeptide repeat kinase activity; ISO:RGD.
DR   GO; GO:0030521; P:androgen receptor signaling pathway; ISO:RGD.
DR   GO; GO:0009887; P:animal organ morphogenesis; ISO:RGD.
DR   GO; GO:0006915; P:apoptotic process; IEA:UniProtKB-KW.
DR   GO; GO:0050853; P:B cell receptor signaling pathway; ISO:RGD.
DR   GO; GO:0060020; P:Bergmann glial cell differentiation; ISO:RGD.
DR   GO; GO:0061308; P:cardiac neural crest cell development involved in heart development; ISO:RGD.
DR   GO; GO:0072584; P:caveolin-mediated endocytosis; TAS:UniProtKB.
DR   GO; GO:0007166; P:cell surface receptor signaling pathway; IBA:GO_Central.
DR   GO; GO:0034198; P:cellular response to amino acid starvation; ISO:RGD.
DR   GO; GO:0071276; P:cellular response to cadmium ion; ISO:RGD.
DR   GO; GO:0071320; P:cellular response to cAMP; IEP:RGD.
DR   GO; GO:0071364; P:cellular response to epidermal growth factor stimulus; IEP:RGD.
DR   GO; GO:1990314; P:cellular response to insulin-like growth factor stimulus; IEP:RGD.
DR   GO; GO:0061431; P:cellular response to methionine; IEP:RGD.
DR   GO; GO:0036120; P:cellular response to platelet-derived growth factor stimulus; IEP:RGD.
DR   GO; GO:0071380; P:cellular response to prostaglandin E stimulus; IEP:RGD.
DR   GO; GO:0034614; P:cellular response to reactive oxygen species; ISO:RGD.
DR   GO; GO:0097237; P:cellular response to toxic substance; IDA:RGD.
DR   GO; GO:0071356; P:cellular response to tumor necrosis factor; ISO:RGD.
DR   GO; GO:0019858; P:cytosine metabolic process; ISO:RGD.
DR   GO; GO:0046697; P:decidualization; IDA:RGD.
DR   GO; GO:0015966; P:diadenosine tetraphosphate biosynthetic process; IMP:CAFA.
DR   GO; GO:0006974; P:DNA damage response; ISO:RGD.
DR   GO; GO:0038127; P:ERBB signaling pathway; ISO:RGD.
DR   GO; GO:0038133; P:ERBB2-ERBB3 signaling pathway; ISO:RGD.
DR   GO; GO:0070371; P:ERK1 and ERK2 cascade; IMP:CAFA.
DR   GO; GO:0044849; P:estrous cycle; IEP:RGD.
DR   GO; GO:0060324; P:face development; ISO:RGD.
DR   GO; GO:0007507; P:heart development; ISO:RGD.
DR   GO; GO:0008286; P:insulin receptor signaling pathway; ISO:RGD.
DR   GO; GO:0048009; P:insulin-like growth factor receptor signaling pathway; ISO:RGD.
DR   GO; GO:0035556; P:intracellular signal transduction; IDA:RGD.
DR   GO; GO:0060716; P:labyrinthine layer blood vessel development; ISO:RGD.
DR   GO; GO:0031663; P:lipopolysaccharide-mediated signaling pathway; ISO:RGD.
DR   GO; GO:0060291; P:long-term synaptic potentiation; ISO:RGD.
DR   GO; GO:0060425; P:lung morphogenesis; ISO:RGD.
DR   GO; GO:0033598; P:mammary gland epithelial cell proliferation; ISO:RGD.
DR   GO; GO:0000165; P:MAPK cascade; IMP:RGD.
DR   GO; GO:0042552; P:myelination; ISO:RGD.
DR   GO; GO:0045596; P:negative regulation of cell differentiation; ISO:RGD.
DR   GO; GO:0014032; P:neural crest cell development; ISO:RGD.
DR   GO; GO:0042473; P:outer ear morphogenesis; ISO:RGD.
DR   GO; GO:0018105; P:peptidyl-serine phosphorylation; IDA:MGI.
DR   GO; GO:0018107; P:peptidyl-threonine phosphorylation; ISS:UniProtKB.
DR   GO; GO:0060045; P:positive regulation of cardiac muscle cell proliferation; IMP:RGD.
DR   GO; GO:0030335; P:positive regulation of cell migration; IEP:RGD.
DR   GO; GO:0008284; P:positive regulation of cell population proliferation; IEP:RGD.
DR   GO; GO:0045893; P:positive regulation of DNA-templated transcription; IMP:CAFA.
DR   GO; GO:0010759; P:positive regulation of macrophage chemotaxis; ISO:RGD.
DR   GO; GO:0120041; P:positive regulation of macrophage proliferation; ISO:RGD.
DR   GO; GO:0010800; P:positive regulation of peptidyl-threonine phosphorylation; ISO:RGD.
DR   GO; GO:0042307; P:positive regulation of protein import into nucleus; IMP:UniProtKB.
DR   GO; GO:1904355; P:positive regulation of telomere capping; ISO:RGD.
DR   GO; GO:0032212; P:positive regulation of telomere maintenance via telomerase; ISO:RGD.
DR   GO; GO:0045727; P:positive regulation of translation; IMP:RGD.
DR   GO; GO:0050847; P:progesterone receptor signaling pathway; ISO:RGD.
DR   GO; GO:0006468; P:protein phosphorylation; IDA:UniProtKB.
DR   GO; GO:0030641; P:regulation of cellular pH; ISO:RGD.
DR   GO; GO:0051493; P:regulation of cytoskeleton organization; TAS:UniProtKB.
DR   GO; GO:2000641; P:regulation of early endosome to late endosome transport; TAS:UniProtKB.
DR   GO; GO:0090170; P:regulation of Golgi inheritance; TAS:UniProtKB.
DR   GO; GO:0030278; P:regulation of ossification; ISO:RGD.
DR   GO; GO:0031647; P:regulation of protein stability; ISS:UniProtKB.
DR   GO; GO:0032872; P:regulation of stress-activated MAPK cascade; TAS:UniProtKB.
DR   GO; GO:0097305; P:response to alcohol; IEP:RGD.
DR   GO; GO:0042220; P:response to cocaine; IEP:RGD.
DR   GO; GO:0070849; P:response to epidermal growth factor; ISS:UniProtKB.
DR   GO; GO:0032355; P:response to estradiol; IEP:RGD.
DR   GO; GO:0043627; P:response to estrogen; IDA:RGD.
DR   GO; GO:0043330; P:response to exogenous dsRNA; ISO:RGD.
DR   GO; GO:0042542; P:response to hydrogen peroxide; IEP:RGD.
DR   GO; GO:0032496; P:response to lipopolysaccharide; ISO:RGD.
DR   GO; GO:0035094; P:response to nicotine; IGI:ARUK-UCL.
DR   GO; GO:0033574; P:response to testosterone; IEP:RGD.
DR   GO; GO:0009636; P:response to toxic substance; IDA:RGD.
DR   GO; GO:0014044; P:Schwann cell development; ISO:RGD.
DR   GO; GO:0019233; P:sensory perception of pain; IMP:UniProtKB.
DR   GO; GO:0043401; P:steroid hormone receptor signaling pathway; ISO:RGD.
DR   GO; GO:0051403; P:stress-activated MAPK cascade; ISO:RGD.
DR   GO; GO:0050852; P:T cell receptor signaling pathway; ISO:RGD.
DR   GO; GO:0048538; P:thymus development; ISO:RGD.
DR   GO; GO:0030878; P:thyroid gland development; ISO:RGD.
DR   GO; GO:0060440; P:trachea formation; ISO:RGD.
DR   CDD; cd07849; STKc_ERK1_2_like; 1.
DR   Gene3D; 1.10.510.10; Transferase(Phosphotransferase) domain 1; 1.
DR   IDEAL; IID50321; -.
DR   InterPro; IPR011009; Kinase-like_dom_sf.
DR   InterPro; IPR050117; MAP_kinase.
DR   InterPro; IPR003527; MAP_kinase_CS.
DR   InterPro; IPR008349; MAPK_ERK1/2.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   PANTHER; PTHR24055; MITOGEN-ACTIVATED PROTEIN KINASE; 1.
DR   PANTHER; PTHR24055:SF599; MITOGEN-ACTIVATED PROTEIN KINASE 1; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PRINTS; PR01770; ERK1ERK2MAPK.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF56112; Protein kinase-like (PK-like); 1.
DR   PROSITE; PS01351; MAPK; 1.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Apoptosis; ATP-binding; Cell cycle;
KW   Cell junction; Cytoplasm; Cytoskeleton; Direct protein sequencing; Kinase;
KW   Membrane; Nucleotide-binding; Nucleus; Phosphoprotein; Reference proteome;
KW   Serine/threonine-protein kinase; Transferase; Ubl conjugation.
FT   INIT_MET        1
FT                   /note="Removed"
FT                   /evidence="ECO:0000269|Ref.2"
FT   CHAIN           2..358
FT                   /note="Mitogen-activated protein kinase 1"
FT                   /id="PRO_0000186249"
FT   DOMAIN          23..311
FT                   /note="Protein kinase"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159"
FT   MOTIF           183..185
FT                   /note="TXY"
FT   ACT_SITE        147
FT                   /note="Proton acceptor"
FT   BINDING         29..37
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:8639522"
FT   BINDING         52
FT                   /ligand="ATP"
FT                   /ligand_id="ChEBI:CHEBI:30616"
FT                   /evidence="ECO:0000255|PROSITE-ProRule:PRU00159,
FT                   ECO:0000269|PubMed:8639522"
FT   MOD_RES         2
FT                   /note="N-acetylalanine"
FT                   /evidence="ECO:0000269|Ref.2"
FT   MOD_RES         27
FT                   /note="Phosphoserine; by SGK1"
FT                   /evidence="ECO:0000250|UniProtKB:P28482"
FT   MOD_RES         183
FT                   /note="Phosphothreonine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         185
FT                   /note="Phosphotyrosine"
FT                   /evidence="ECO:0007744|PubMed:22673903"
FT   MOD_RES         188
FT                   /note="Phosphothreonine; by autocatalysis"
FT                   /evidence="ECO:0000250|UniProtKB:P28482"
FT   MOD_RES         244
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P28482"
FT   MOD_RES         246
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P28482"
FT   MOD_RES         282
FT                   /note="Phosphoserine"
FT                   /evidence="ECO:0000250|UniProtKB:P28482"
FT   MUTAGEN         117
FT                   /note="Q->A: Reduced affinity for DCC. Strongly reduced
FT                   affinity for DCC; when associated with A-123."
FT                   /evidence="ECO:0000269|PubMed:21070949"
FT   MUTAGEN         123
FT                   /note="H->A: Reduced affinity for DCC. Strongly reduced
FT                   affinity for DCC; when associated with A-117."
FT                   /evidence="ECO:0000269|PubMed:21070949"
FT   MUTAGEN         155
FT                   /note="L->A: Reduced affinity for DCC."
FT                   /evidence="ECO:0000269|PubMed:21070949"
FT   STRAND          10..17
FT                   /evidence="ECO:0007829|PDB:5HD4"
FT   TURN            20..22
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          23..31
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          33..42
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   TURN            43..46
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          47..54
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          57..59
FT                   /evidence="ECO:0007829|PDB:6FXV"
FT   HELIX           60..75
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          86..88
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   TURN            93..95
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          99..104
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          107..109
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           110..116
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           121..140
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           150..152
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          153..155
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          161..163
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          170..172
FT                   /evidence="ECO:0007829|PDB:3O71"
FT   HELIX           174..176
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   TURN            179..181
FT                   /evidence="ECO:0007829|PDB:2ERK"
FT   HELIX           182..184
FT                   /evidence="ECO:0007829|PDB:3O71"
FT   HELIX           189..191
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           194..196
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   TURN            197..199
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   TURN            200..202
FT                   /evidence="ECO:0007829|PDB:6OPK"
FT   HELIX           206..221
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           231..242
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           247..251
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           256..264
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           273..276
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   STRAND          278..280
FT                   /evidence="ECO:0007829|PDB:2ERK"
FT   HELIX           282..291
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   TURN            296..298
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           302..306
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           309..311
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   TURN            312..314
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           317..319
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           331..333
FT                   /evidence="ECO:0007829|PDB:4N4S"
FT   STRAND          334..336
FT                   /evidence="ECO:0007829|PDB:6OT6"
FT   HELIX           338..348
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           350..352
FT                   /evidence="ECO:0007829|PDB:4S32"
FT   HELIX           354..356
FT                   /evidence="ECO:0007829|PDB:1GOL"
SQ   SEQUENCE   358 AA;  41276 MW;  3BBCF22471EDBA0B CRC64;
     MAAAAAAGPE MVRGQVFDVG PRYTNLSYIG EGAYGMVCSA YDNLNKVRVA IKKISPFEHQ
     TYCQRTLREI KILLRFRHEN IIGINDIIRA PTIEQMKDVY IVQDLMETDL YKLLKTQHLS
     NDHICYFLYQ ILRGLKYIHS ANVLHRDLKP SNLLLNTTCD LKICDFGLAR VADPDHDHTG
     FLTEYVATRW YRAPEIMLNS KGYTKSIDIW SVGCILAEML SNRPIFPGKH YLDQLNHILG
     ILGSPSQEDL NCIINLKARN YLLSLPHKNK VPWNRLFPNA DSKALDLLDK MLTFNPHKRI
     EVEQALAHPY LEQYYDPSDE PIAEAPFKFD MELDDLPKEK LKELIFEETA RFQPGYRS
//
